BiotechTube
HekeTiss

HekeTiss

Zurich, Switzerland· Est.
heketiss.ch
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

HekeTiss is a private, pre-revenue biotech company developing an innovative cell therapy for chronic wounds, a major unmet need affecting over 1% of the global population. Its core technology involves functionally enhancing adipose-derived stem cells to create TrophiPatch™, a bioresorbable cellular sponge currently in first-in-human clinical studies. The company, led by its scientific founders and supported by Swiss innovation grants, aims to provide an effective, off-the-shelf solution to transform the standard of care in wound management.

Chronic WoundsDiabetic Foot Ulcers

Technology Platform

Proprietary platform for the functional enhancement of adipose-derived stem/stromal cells (ASCs) to create off-the-shelf, bioresorbable cellular patches for tissue regeneration.

Opportunities

The large and growing global market for chronic wound care, driven by diabetes and aging populations, presents a significant commercial opportunity.
An effective, convenient, off-the-shelf cell therapy could capture substantial market share from current suboptimal standards of care.
Support from the robust Swiss innovation grant system provides non-dilutive capital to advance development.

Risk Factors

The lead candidate faces inherent clinical trial risks regarding efficacy and safety.
Regulatory pathways for cell-based therapies are complex and uncertain.
The company will eventually face intense competition from other advanced wound care products and therapies in development.

Competitive Landscape

HekeTiss competes in the advanced wound care and cell therapy space, which includes companies developing growth factors (e.g., Regranex), skin substitutes (e.g., Integra, Apligraf), and other cell-based therapies. Its key differentiator is the proprietary functional enhancement of adipose-derived stem cells in an off-the-shelf patch format, aiming for improved vascularization and healing.

More companies in Switzerland →